Cargando…
Deciphering tumor immune microenvironment differences between high-grade serous and endometrioid ovarian cancer to investigate their potential in indicating immunotherapy response
BACKGROUND: Ovarian cancer is a significant public health concern with a poor prognosis for epithelial ovarian cancer. To explore the potential of immunotherapy in treating epithelial ovarian cancer, we investigated the immune microenvironments of 52 patients with epithelial ovarian cancer, includin...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10664484/ https://www.ncbi.nlm.nih.gov/pubmed/37993916 http://dx.doi.org/10.1186/s13048-023-01284-1 |
_version_ | 1785148743904919552 |
---|---|
author | Yang, Hua Gu, Xiangyu Fan, Rong Zhu, Qun Zhong, Sen Wan, Xirun Chen, Qian Zhu, Lan Feng, Fengzhi |
author_facet | Yang, Hua Gu, Xiangyu Fan, Rong Zhu, Qun Zhong, Sen Wan, Xirun Chen, Qian Zhu, Lan Feng, Fengzhi |
author_sort | Yang, Hua |
collection | PubMed |
description | BACKGROUND: Ovarian cancer is a significant public health concern with a poor prognosis for epithelial ovarian cancer. To explore the potential of immunotherapy in treating epithelial ovarian cancer, we investigated the immune microenvironments of 52 patients with epithelial ovarian cancer, including 43 with high-grade serous ovarian cancer and 9 with endometrioid ovarian cancer. RESULTS: Fresh tumor tissue was analyzed for genetic mutations and various parameters related to immune evasion and infiltration. The mean stromal score (stromal cell infiltration) in high-grade serous ovarian cancer was higher than in endometrioid ovarian cancer. The infiltration of CD8 T cells and exhausted CD8 T cells were found to be more extensive in high-grade serous ovarian cancer. Tumor Immune Dysfunction and Exclusion scores, T cell exclusion scores, and cancer-associated fibroblasts (CAF) scores were also higher in the high-grade serous ovarian cancer group, suggesting that the number of cytotoxic lymphocytes in the tumor microenvironment of high-grade serous ovarian cancer is likely lower compared to endometrioid ovarian cancer. CONCLUSIONS: The high mean stromal score and more extensive infiltration and exhaustion of CD8 T cells in high-grade serous ovarian cancer indicate that high-grade serous ovarian cancer exhibits a higher level of cytotoxic T cell infiltration, yet these T cells tend to be in a dysfunctional state. Higher Tumor Immune Dysfunction and Exclusion scores, T cell exclusion scores, and CAF scores in high-grade serous ovarian cancers suggest that immune escape is more likely to occur in high-grade serous ovarian cancer, thus endometrioid ovarian cancer may be more conducive to immunotherapy. Therefore, it is crucial to design immunotherapy clinical trials for ovarian cancer to distinguish between high-grade serous and endometrioid ovarian cancer from the outset. This distinction will help optimize treatment strategies and improve outcomes for patients with different subtypes. |
format | Online Article Text |
id | pubmed-10664484 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-106644842023-11-22 Deciphering tumor immune microenvironment differences between high-grade serous and endometrioid ovarian cancer to investigate their potential in indicating immunotherapy response Yang, Hua Gu, Xiangyu Fan, Rong Zhu, Qun Zhong, Sen Wan, Xirun Chen, Qian Zhu, Lan Feng, Fengzhi J Ovarian Res Research BACKGROUND: Ovarian cancer is a significant public health concern with a poor prognosis for epithelial ovarian cancer. To explore the potential of immunotherapy in treating epithelial ovarian cancer, we investigated the immune microenvironments of 52 patients with epithelial ovarian cancer, including 43 with high-grade serous ovarian cancer and 9 with endometrioid ovarian cancer. RESULTS: Fresh tumor tissue was analyzed for genetic mutations and various parameters related to immune evasion and infiltration. The mean stromal score (stromal cell infiltration) in high-grade serous ovarian cancer was higher than in endometrioid ovarian cancer. The infiltration of CD8 T cells and exhausted CD8 T cells were found to be more extensive in high-grade serous ovarian cancer. Tumor Immune Dysfunction and Exclusion scores, T cell exclusion scores, and cancer-associated fibroblasts (CAF) scores were also higher in the high-grade serous ovarian cancer group, suggesting that the number of cytotoxic lymphocytes in the tumor microenvironment of high-grade serous ovarian cancer is likely lower compared to endometrioid ovarian cancer. CONCLUSIONS: The high mean stromal score and more extensive infiltration and exhaustion of CD8 T cells in high-grade serous ovarian cancer indicate that high-grade serous ovarian cancer exhibits a higher level of cytotoxic T cell infiltration, yet these T cells tend to be in a dysfunctional state. Higher Tumor Immune Dysfunction and Exclusion scores, T cell exclusion scores, and CAF scores in high-grade serous ovarian cancers suggest that immune escape is more likely to occur in high-grade serous ovarian cancer, thus endometrioid ovarian cancer may be more conducive to immunotherapy. Therefore, it is crucial to design immunotherapy clinical trials for ovarian cancer to distinguish between high-grade serous and endometrioid ovarian cancer from the outset. This distinction will help optimize treatment strategies and improve outcomes for patients with different subtypes. BioMed Central 2023-11-22 /pmc/articles/PMC10664484/ /pubmed/37993916 http://dx.doi.org/10.1186/s13048-023-01284-1 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Yang, Hua Gu, Xiangyu Fan, Rong Zhu, Qun Zhong, Sen Wan, Xirun Chen, Qian Zhu, Lan Feng, Fengzhi Deciphering tumor immune microenvironment differences between high-grade serous and endometrioid ovarian cancer to investigate their potential in indicating immunotherapy response |
title | Deciphering tumor immune microenvironment differences between high-grade serous and endometrioid ovarian cancer to investigate their potential in indicating immunotherapy response |
title_full | Deciphering tumor immune microenvironment differences between high-grade serous and endometrioid ovarian cancer to investigate their potential in indicating immunotherapy response |
title_fullStr | Deciphering tumor immune microenvironment differences between high-grade serous and endometrioid ovarian cancer to investigate their potential in indicating immunotherapy response |
title_full_unstemmed | Deciphering tumor immune microenvironment differences between high-grade serous and endometrioid ovarian cancer to investigate their potential in indicating immunotherapy response |
title_short | Deciphering tumor immune microenvironment differences between high-grade serous and endometrioid ovarian cancer to investigate their potential in indicating immunotherapy response |
title_sort | deciphering tumor immune microenvironment differences between high-grade serous and endometrioid ovarian cancer to investigate their potential in indicating immunotherapy response |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10664484/ https://www.ncbi.nlm.nih.gov/pubmed/37993916 http://dx.doi.org/10.1186/s13048-023-01284-1 |
work_keys_str_mv | AT yanghua decipheringtumorimmunemicroenvironmentdifferencesbetweenhighgradeserousandendometrioidovariancancertoinvestigatetheirpotentialinindicatingimmunotherapyresponse AT guxiangyu decipheringtumorimmunemicroenvironmentdifferencesbetweenhighgradeserousandendometrioidovariancancertoinvestigatetheirpotentialinindicatingimmunotherapyresponse AT fanrong decipheringtumorimmunemicroenvironmentdifferencesbetweenhighgradeserousandendometrioidovariancancertoinvestigatetheirpotentialinindicatingimmunotherapyresponse AT zhuqun decipheringtumorimmunemicroenvironmentdifferencesbetweenhighgradeserousandendometrioidovariancancertoinvestigatetheirpotentialinindicatingimmunotherapyresponse AT zhongsen decipheringtumorimmunemicroenvironmentdifferencesbetweenhighgradeserousandendometrioidovariancancertoinvestigatetheirpotentialinindicatingimmunotherapyresponse AT wanxirun decipheringtumorimmunemicroenvironmentdifferencesbetweenhighgradeserousandendometrioidovariancancertoinvestigatetheirpotentialinindicatingimmunotherapyresponse AT chenqian decipheringtumorimmunemicroenvironmentdifferencesbetweenhighgradeserousandendometrioidovariancancertoinvestigatetheirpotentialinindicatingimmunotherapyresponse AT zhulan decipheringtumorimmunemicroenvironmentdifferencesbetweenhighgradeserousandendometrioidovariancancertoinvestigatetheirpotentialinindicatingimmunotherapyresponse AT fengfengzhi decipheringtumorimmunemicroenvironmentdifferencesbetweenhighgradeserousandendometrioidovariancancertoinvestigatetheirpotentialinindicatingimmunotherapyresponse |